Microgranules insoluble in gastric fluid, method for obtaining same and pharmaceutical preparations
First Claim
Patent Images
1. A microgranule comprising a gastric proton pump inhibitor, with the exception of omeprazole, comprising an active layer comprising the proton pump inhibitor and an outer layer for protection in gastric fluid, wherein:
- (A) the active layer is applied to a neutral nucleus;
(B) the active layer comprises at least one hydrophobic substance chosen from silicone oils and present in the active layer in an amount of between 5 and 40% by weight of the gastric proton pump inhibitor;
(C) and the layer for protection in gastric fluid comprises at least one hydrophobic substance chosen from glycerides and present in the layer for protection in gastric fluid in an amount of 5 to 20% by weight of the protective layer; and
further wherein the microgranule has no alkaline compound and no ionic surfactant.
3 Assignments
0 Petitions
Accused Products
Abstract
A pharmaceutical formulation of a gastric proton pump inhibitor, with the exception of omeprazole, is disclosed. The formulation is in the form of microgranules insoluble in gastric fluid having improved stability over time. The formulation comprises several hydrophobic substances chosen in order to increase the stability of the active principle while obtaining the desired dissolution profile.
-
Citations
22 Claims
-
1. A microgranule comprising a gastric proton pump inhibitor, with the exception of omeprazole, comprising an active layer comprising the proton pump inhibitor and an outer layer for protection in gastric fluid, wherein:
-
(A) the active layer is applied to a neutral nucleus; (B) the active layer comprises at least one hydrophobic substance chosen from silicone oils and present in the active layer in an amount of between 5 and 40% by weight of the gastric proton pump inhibitor; (C) and the layer for protection in gastric fluid comprises at least one hydrophobic substance chosen from glycerides and present in the layer for protection in gastric fluid in an amount of 5 to 20% by weight of the protective layer; and
further wherein the microgranule has no alkaline compound and no ionic surfactant. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)
-
-
22. A microgranule comprising a gastric proton pump inhibitor, with the exception of omeprazole, comprising an active layer comprising the proton pump inhibitor and an outer layer for protection in gastric fluid, wherein:
-
(A) the active layer is applied to a single neutral nucleus; (B) the active layer comprises at least one hydrophobic substance chosen from silicone oils and present in the active layer in an amount of between 5 and 40% by weight of the gastric proton pump inhibitor; (C) and the layer for protection in gastric fluid comprises at least one hydrophobic substance chosen from glycerides and present in the layer for protection in gastric fluid in an amount of 5 to 20% by weight of the protective layer; and further wherein the microgranule has no alkaline compound and no ionic surfactant.
-
Specification